Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
SRDX Stock Down Despite FDA Clearance for Pounce XL System
by Zacks Equity Research
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
by Zacks Equity Research
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.90% and 0.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Markets: Chewy, Pitney Bowes, 3M in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
by Zacks Equity Research
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
by Zacks Equity Research
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
What's in Store for These 4 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 119.44% and 11.02%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -14.29% and 0.49%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for April 9th
by Zacks Equity Research
SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?